DaShenLin Expands Access to Leqembi® (Inclisiran Sodium Injection) to Meet Growing Lipid-Lowering Treatment Demand
Novartis
Drug Development and Manufacturing
Recently, Novartis' blockbuster new drug Leke Wei®(Inclisiran Sodium Injection)The first dose has been administered in Beijing, Shanghai and other places. Currently, the drug is gradually entering out-of-hospital pharmacies.
According toDaShenLin NewSpecialty Drug Service CenterThe official WeChat shows,Recently, Novartis'重磅 new drug Lekewei®(Inclisiran Sodium Injection) officially went on sale at DaShenLin New Special Drug Service Center and completed the first transaction at DaShenLin on October 18.
Source:DaShenLin Specialty Drug Service Center
According to the official Weibo, at 21:35 on October 17, Novartis Leke Wei®(General Name:Inclisiran Sodium Injection) arrived at DaShenLin Pharmaceutical Group Co., Ltd. warehouse for acceptance and was completed on the same night.22:00Arrive at DaShenLin Specialty Drug Service Center for shelving.
On August 22 this year, Le Ke Wei®(Inclisiran Sodium Injection) has been approved by the China National Medical Products Administration as an adjunct to diet for the treatment of adult patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia.Because it only needs to be injected twice a year，Attract Attention and DiscussionOn。
Inclisiran Sodium InjectionPriced at 9,988 yuan per injection. IndustryInsiders believe that,Inclisiran Sodium Injection Ushters in a New Era of Lipid Management, Assisting Doctors and Patients in Long-term Lipid Control with Greater Convenience and Enhancing Patients' Quality of Life.
In less than two months, DaShenLin Pharmaceutical Group Co., Ltd. has introduced and stockedInclisiran Sodium Injection, this move is also considered to be a reflection of DaShenLin Pharmaceutical Group Co., Ltd. deeply exploring consumer needs and continuously updating and iterating its products.
With the aggravation of aging, the increase in the number of people with chronic diseases, and the implementation of the "dual channel" policy and online prescription drug sales, the terminal value of pharmacies has become increasingly prominent. Data from Menet shows that the proportion of retail pharmacy terminal drug sales in China increased from 23.4% in 2019 to 29.0% in 2022, rising by 5.6 percentage points.
The market generally believes that a series of medical reform policies will accelerate the outflow of hospital prescriptions, driving the flow of drug sales and customer traffic to the off-hospital market. Retail pharmacies, with advantages such as convenience, service motivation, and service awareness, will play an important role and function in the co-management of chronic diseases and science popularization education.
In recent years, DaShenLin Pharmaceutical Group Co., Ltd. has actively undertaken external prescriptions, with measures including: expanding hospital-adjacent stores, DTP (Direct to Patient), specialized pharmacies for chronic and special outpatient services, strengthening professional service capabilities and the prescription drug supply system, and aligning with prescription flow mechanisms. With the introduction of policies such as the "dual channel" management mechanism for national medical insurance negotiation drugs and the inclusion of designated retail pharmacies into outpatient coordinated management, these have promoted the access of medical insurance pooled accounts to retail pharmacies, broadened patients' payment methods in retail pharmacies, and further facilitated the outflow of hospital prescriptions to off-premises channels.
In response, DaShenLin Pharmaceutical Group Co., Ltd. actively pursued the qualification for dual-channel and outpatient care coordination designated stores. As of June 30 this year, DaShenLin had 209 DTP stores, 1,449 stores with various medical insurance coordination reimbursement qualifications, including 745 stores connected to outpatient care coordination and 554 dual-channel stores (there is some overlap in the number of outpatient care coordination and dual-channel stores).
In addition, DaShenLin Pharmaceutical Group Co., Ltd. is actively exploring a value-added model that combines pharmaceuticals and insurance services. It is gradually promoting commercial insurance brokerage and reimbursement services across China, establishing a closed-loop business model of "Medical + Pharmaceutical + Care + Testing + Insurance." This helps patients access cutting-edge medications and medical services at lower costs and through more convenient channels, reducing the financial burden of using innovative drugs while improving healthcare efficiency. This creates a virtuous cycle, further driving the sales of pharmaceuticals, especially innovative drug varieties.